Pumitamig is the class's clearest test of whether targeting PD-L1 rather than PD-1 matters. BioNTech's timelines are also the ...
Under the terms of the agreement, Rona will receive upfront and near-term milestone payments of up to $100M and is eligible ...
Funding Will Accelerate Development of a Nanofluidic Antiretroviral Implant Designed to Deliver Continuous HIV Protection for ...
NueCell Bio, a translational development partner that helps advance cell therapies from scientific discovery to GMP readiness ...
Takeda’s First-in-Class Narcolepsy Drug ORZEYFUL Enters Japan and China Markets Following Regulatory Approvals ...
- Celltrion, Inc. (KRX:068270) has announced its participation in the United European Gastroenterology (UEG) Week 2026 to be ...
Danaher Corporation announced a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of ...
BioAgilytix company, announced the opening of a new Australian laboratory in Sydney, expanding its national footprint to four ...
Shanghai Ark Biopharmaceutical Secures US FDA IND Clearance for Phase II Trial of Long-Acting Influenza Prevention Drug ...
In preclinical studies, ISM9546 exhibited sub-nanomolar VAV1 degradation potency across multiple cell-based assays. Oral ...
South Korea’s GCCL and LabConnect Partner to Strengthen Global Clinical Trial Operations Across APAC and North America ...
Exclusive agreement grants Visara worldwide rights outside Greater China to develop HT006.2.2 for neurotrophic keratitis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results